|
|
 |
|
Viewing report
|
|
|
|
Triple Analysis: The Drug Target Atlas of Apoptopic Drugs in Oncology and Special Focus on Breast and Prostate Cancer
Bioseeker, Feb 2008, Pages: 450
This is the report for professionals interested to grasp the field of apoptopic drug targets in oncology and at the same time have an extensive R&D overview of breast- and prostate cancer. This extensive 450+ pages report compiles and analyzes Apoptosis, the type of death about whose genetically controlled pathways we know the most, and further gives an in depth analysis in two key oncology areas; Breast- and Prostate cancer
In the report, the author reports on 90 unique drug target combinations, each comprised of a different collection or mix of individually defined targets, for 114 apoptopic drugs designed for the treatment of 48 different cancer indications.
To fuel the scientific and competitive thinking, the author opens the gate into the presence and relevance of protein-protein interactions between identified targets of apoptopic drugs. No less than 452 protein-protein interactions were recognized among 96 of the 119 included apoptopic drug targets.
This report section by the numbers
- A hundred different tables. Includes more than 1,500 active links to related resources on the Internet
- 114 apoptopic drugs, under development by 87 investigators, are included, covering more than 430 developmental projects in cancer
- 119 Unique, in-depth, drug target profiles, highlighting twelve themes about the drug target, i.e. protein-protein interaction with other apoptopic drug targets, linked cancer indications, drugs under development, compound types, presence in the Cancer Genome Project etc.
- 90 Unique drug target combinations of apoptopic drugs
- 452 protein-protein interactions among apoptopic drug targets
- Extensive pathway analysis of drug targets
In breast cancer we have identified 170 drug candidates in clinical stage of development and more than 100 companies are involved in the development of these drugs. As a treatment for breast cancer hormone modifying therapies together with different chemotherapeutic schedules have been of highest interest during the last years of progress. A vast amount of new clinical research data has emerged and several new clinical trials have been initiated and others generated new results. Protein kinase inhibitors and epothilones have generated substantial amount of new research data in this field. But, other strategies seem not successful and we are still waiting new information regarding their progress.
In prostate cancer we have identified 127 drug candidates in phase II or III stage of development and more than 85 companies are involved in the development of these drugs. Two of the most successful strategies are apoptosis inducers and cell based vaccines. Three out of 10 late stage candidates are apoptosis inducers. Cell based vaccines has been tried for some time but has so far failed to generate substantial improvements.
The Breast and Prostate Cancer section highlights
- Thorough examination of status and impact of several novel drugs in development
- Discussion of the challenges in current and future treatment strategies
- Anticancer pipeline of most companies in the field
Key reasons to read this report
- This report serves as a serious reference for professionals interested in the development of oncology drug targets and selection/validation of targeting strategies.
- Explore the strengths and weaknesses associated with compounds in clinical development. Scientific rationale for most novel therapeutics in breast- and prostate cancer R&D, and the results of clinical trials to date
- Gain insight into the current challenges and commercial opportunities associated with breast- and prostate cancer therapy
Customers who bought this item also bought
Triple Analysis: The Drug Target Atlas of Apoptopic Drugs in Oncology and Special Focus on Lung Cancer and Melanoma
The Drug Target Atlas of Protein Kinase Inhibitors in Oncology
Antibody Drug Targets and Focus on Breast & Prostate Cancer
Prostate and Breast Cancer- New Treatments & Developmental Progress
Currently Druggable in Colorectal Cancer: A Drug Target Competitive Analysis
Cancer Drug Resistance
Currently Druggable in Prostate Cancer: A Drug Target Competitive Analysis
Drug Delivery in Cancer - Technologies, Markets and Companies
Currently Druggable in Breast Cancer: A Drug Target Competitive Analysis
Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Breast- and Prostate Cancer
Breast Cancer - Therapeutic And Competitive Insights
Competitive Insights to Anti-Angiogenic Drug R&D in Oncology
|
|
|
|
